SLC16A1 and neoplasm: Recent studies have demonstrated that AZD3965 and structurally related MCT1 inhibitors can prevent lactate efflux in highly glycolytic tumour types that lack MCT4, inducing a feedback inhibition of glycolytic flux that can impart a significant anti-proliferative effect [6, 7].